Psychedelic-assisted therapy pairs a supervised drug session with preparation and integration psychotherapy. The evidence is promising but uneven: MDMA-assisted therapy reduced PTSD symptoms versus placebo-plus-therapy in Phase 2 and 3 trials with benefits held at 12 months, psilocybin has its strongest data in treatment-resistant depression and end-of-life anxiety, and ketamine is the only FDA-approved option. Key caveats are strict exclusion criteria, near-impossible blinding, and limited long-term safety data. MDMA and psilocybin remain Schedule I federally.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does psychedelic therapy work for PTSD?
For MDMA, the signal is real: Phase 2 and 3 trials showed significantly greater PTSD symptom reduction than placebo plus therapy, maintained at 12-month follow-up. Psilocybin for trauma is earlier-stage; its strongest evidence is in treatment-resistant depression and end-of-life anxiety.
Is psychedelic-assisted therapy legal?
Mostly not yet. MDMA and psilocybin are Schedule I federally, with MDMA's FDA application pending after Phase 3. Ketamine is legal by prescription and FDA-approved for depression as Spravato. Oregon and Colorado have legalized psilocybin in defined contexts; elsewhere, clinical trials are the legitimate route.
Is it safe?
In screened, supervised settings the main risks are psychological distress during sessions, headaches, blood-pressure and heart-rate elevation (especially with MDMA), and destabilization in vulnerable people. A personal or family history of psychosis or bipolar disorder is contraindicated. Long-term safety data are limited.
Is it just taking drugs?
No. The studied model is a package: medical and psychological screening, preparatory sessions, a long medicine session with two therapists present, then multiple integration sessions over weeks. The drug is argued to open a window; the therapy is the treatment.
What would change this rating?
An FDA decision on MDMA for PTSD, plus trials that solve the blinding problem and recruit beyond the narrow eligible populations. Psilocybin Phase 3 readouts in depression are the other watch item.
02Overview
Psychedelic-Assisted Therapy (PAT) combines the careful administration of psychedelic substances (MDMA, psilocybin, ketamine, and others) with psychotherapeutic support to treat mental health conditions, particularly treatment-resistant PTSD, depression, and anxiety. After decades of prohibition, this field is experiencing a renaissance of clinical research with remarkably promising results.
"MDMA may prove to be a breakthrough treatment for difficult cases of Post-Traumatic Stress Disorder."
03Key Substances in Clinical Use
MDMA-Assisted Therapy (MDMA-AT)
Mechanism: - Increases serotonin, dopamine, and norepinephrine release - Reduces activity in the amygdala (fear center), decreasing threat response - Increases activity in the prefrontal cortex, enabling cognitive processing - Enhances feelings of trust, empathy, and connection — creating optimal conditions for trauma processing - Allows patients to revisit traumatic memories without being overwhelmed
Evidence: - Multiple Phase 2 and Phase 3 trials show significant reduction in PTSD symptoms - In MAPS-sponsored trials, PTSD symptom severity significantly decreased more for MDMA-AT vs. placebo + therapy - Benefits maintained at 12-month follow-up - Being studied for group therapy format (Dr. Christopher Stauffer, OHSU/Portland VA)
Session structure: - Multiple preparatory sessions with therapists - 2-3 MDMA sessions (8-hour sessions with two therapists present) - Integration sessions between and after dosing sessions - Total treatment course: ~12 weeks
Psilocybin-Assisted Therapy (P-AT)
Mechanism: - Active compound psilocin binds to serotonin 5-HT2A receptors - Profoundly alters default mode network (DMN) activity — the brain network associated with ego/self-narrative - Increases brain connectivity between normally segregated regions - Creates a "reset" effect on rigid thought patterns
Evidence for PTSD: - Researchers have begun pairing psilocybin with various forms of psychotherapy - Showing promise for trauma-related conditions - Strongest evidence for: treatment-resistant depression, end-of-life anxiety, substance use disorders
Other applications: - Depression (including treatment-resistant) - End-of-life anxiety and existential distress - Alcohol and tobacco addiction - OCD - Cluster headaches
Ketamine-Assisted Therapy
Mechanism: - NMDA receptor antagonist - Rapidly increases BDNF (brain-derived neurotrophic factor) — promoting neural plasticity - Dissociative effects create psychological distance from traumatic material - Can produce rapid antidepressant effects (within hours)
Applications: - Treatment-resistant depression (strongest evidence) - Suicidal ideation (rapid relief) - PTSD (emerging evidence) - Chronic pain
04The Therapeutic Framework
Psychedelic-assisted therapy is NOT simply "taking drugs." The therapeutic framework includes:
1. Screening and Preparation
- Rigorous medical and psychological eligibility criteria
- Exclusion criteria: active psychosis, bipolar mania, certain cardiovascular conditions, pregnancy
- Multiple preparation sessions to establish trust and set intentions
- Teaching self-regulation skills
2. The Medicine Session
- Conducted in a comfortable, specially designed setting
- Two trained therapists present throughout
- Eye mask, curated music playlist
- 6-8 hours (MDMA/psilocybin); 1-2 hours (ketamine)
- Client is encouraged to turn inward and explore
3. Integration
- Processing the experience in follow-up therapy sessions
- Journaling, art, movement
- Implementing insights into daily life
- Multiple integration sessions over weeks
05Current Research Landscape
| Substance | Condition | Status |
|---|---|---|
| MDMA | PTSD | Phase 3 complete; seeking FDA approval |
| Psilocybin | Depression | Phase 2/3; Oregon legalized |
| Psilocybin | End-of-life anxiety | Phase 2 completed |
| Ketamine | Depression | FDA-approved (Spravato) |
| MDMA | Social anxiety (autism) | Phase 2 |
| Psilocybin | Substance use disorders | Phase 2 |
Swipe table →
06Important Considerations
Limitations of Current Research
- Studies use rigorous exclusion criteria — many people with PTSD don't qualify
- Masking challenges — participants often know whether they received active drug or placebo
- Long-term safety data still limited
- Need more diverse participant populations
Legal Status
- Varies by jurisdiction — check local laws
- MDMA and psilocybin remain Schedule I in the US (though this is changing)
- Ketamine is legally available with prescription
- Oregon and Colorado have legalized psilocybin in certain contexts
- Clinical trials are available in many locations
Risks
- Psychological distress during sessions (manageable with trained therapists)
- Headaches (especially with psilocybin)
- Blood pressure/heart rate elevation (especially with MDMA)
- Potential for destabilization in vulnerable individuals
- Contraindicated for those with personal/family history of psychosis or bipolar disorder
07Connections
08Sources
09Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.